Acyclovir 400 Stada® tablets are used for the following indications:
- treatment of viral infections of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes;
- suppression (prevention of relapses) of infections caused by the herpes simplex virus in patients with normal immunity;
- prevention of infections caused by the herpes simplex virus in patients with immunodeficiency;
- treatment of infections caused by the Varicella zoster virus (chickenpox and herpes zoster).
Mode of application
The tablet should be taken whole with water. When using high doses of acyclovir, an adequate level of hydration should be maintained.
Adults
To treat infections caused by the herpes simplex virus, it is necessary to take acyclovir tablets at a dose of 200 mg 5 times a day at approximately 4-hour intervals, with the exception of the night period. Treatment should continue for 5 days, but in case of severe primary infection it can be continued. For patients with severe immunodeficiency (for example, after bone marrow transplantation) or for patients with reduced intestinal absorption, the dose can be doubled to 400 mg or the appropriate dose can be used intravenously. Treatment should begin as soon as possible after the onset of infection. In the case of recurrent herpes, it is better to start treatment in the prodromal period or after the first signs of skin lesions appear.
Prevention of relapses (suppressive therapy) of infections caused by the herpes simplex virus. In patients with normal immunity, to prevent relapses of infections caused by the herpes simplex virus, take 200 mg tablets 4 times a day at 6-hour intervals. For convenience, most patients can take 400 mg of acyclovir twice daily at 12-hour intervals. Treatment will be effective even after reducing the dose of acyclovir to 200 mg, which should be taken 3 times a day with an 8-hour interval or even 2 times a day with a 12-hour interval. In some patients, radical improvement is observed after taking a daily dose of acyclovir 800 mg. To monitor for possible changes in the natural history of the disease, acyclovir therapy should be periodically interrupted at intervals of 6-12 months.
Prevention of infections caused by the herpes simplex virus. To prevent infections caused by the herpes simplex virus in patients with immunodeficiency, 200 mg tablets should be taken 4 times a day at 6-hour intervals. For patients with significant immunodeficiency (for example, after bone marrow transplantation) or for patients with reduced intestinal absorption, the dose can be doubled to 400 mg or the appropriate dose can be used intravenously. The duration of prophylaxis depends on the length of the risk period.
To treat infections caused by chickenpox and herpes zoster viruses, you need to take 800 mg tablets 5 times a day at 4-hour intervals, with the exception of the night period. Treatment should continue for 7 days. In patients with severe immunodeficiency (for example, after bone marrow transplantation) or patients with reduced absorption in the intestine, it is better to use intravenous administration. Treatment should begin as soon as possible after the onset of the disease; the result will be better if treatment is started immediately after the appearance of the rash.
Children
For the treatment and prevention of infections caused by the herpes simplex virus in children with immunodeficiency over the age of 2 years, doses as for adults can be used.
For the treatment of chickenpox in children over 6 years of age, prescribe 800 mg of acyclovir 4 times a day; children aged 2 to 6 years can receive 400 mg of acyclovir 4 times a day. The duration of treatment is 5 days.
A more accurate dose can be calculated based on the child’s body weight: 20 mg/kg body weight per day (do not exceed 800 mg) of acyclovir in 4 divided doses.
Children under 2 years of age should not use this dosage form of the drug.
Instructions for use of ACICLOVIR
Adults:
Infections caused by Herpes simplex viruses types 1 and 2:
200 mg 5 times a day with an interval of 4 hours (except for the period of night sleep). The course of treatment usually lasts 5 days, but can be increased according to the patient's condition and response to therapy. In patients with immunodeficiency (for example, after bone marrow transplantation) or in patients with impaired absorption from the intestine, the dose may be increased to 400 mg 5 times a day or the possibility of intravenous use of the drug should be considered.
Prevention of recurrent infections caused by Herpes simplex viruses types 1 and 2:
- in patients with a normal immune system:
200 mg 4 times / day with an interval of 6 hours or 400 mg 2 times / day with an interval of 12 hours between doses. The use of the drug should be started as soon as possible after the infection occurs; in case of relapses, it is recommended to begin use in the prodromal period or after the first signs of infection appear. For many patients, the desired effect can be achieved using 200 mg twice a day with an interval of 12 hours. In some patients, relapses can be observed at a dose of 800 mg / day. - in patients with immunodeficiency:
200 mg 4 times / day with an interval of 6 hours. In patients with severe immunodeficiency (for example, after bone marrow transplantation) or in patients with impaired absorption from the intestine, the dose can be increased to 400 mg 5 times / day or it is necessary to consider the possibility of intravenous use of the drug.
Treatment should be interrupted every 6-12 months to study possible changes in the course of the disease.
The duration of prophylactic use is determined by the length of the period of risk of infection.
Infections caused by Varicella zoster:
800 mg 5 times a day with an interval of 4 hours (except for the period of night sleep). Treatment should last for 7 days.
For patients with immunodeficiency
it is necessary to consider the possibility of intravenous use of the drug.
Treatment with acyclovir will be more effective if started as soon as possible after the rash appears.
Treatment of chickenpox
in immunocompromised patients should be started within 24 hours of the onset of the rash.
- Varicella (Chicken pox):
20 mg/kg body weight (not to exceed 800 mg) every 8 hours for five days. Treatment should be started when the first signs and symptoms of the disease appear. - 2-5 years - 400 mg 1 time / day;
- children under 2 years old
- 200 mg 1 time / day.
Adults (if kidney function is impaired):
In the treatment and prevention of infections caused by Herpes simplex viruses,
in patients with severe renal impairment (creatinine clearance <10 ml/min), a dose reduction to 200 mg of acyclovir twice daily with an interval of 12 hours is recommended.
In the treatment of chickenpox
in patients with severe renal impairment (creatinine clearance less than 10 ml/min), it is recommended to adjust the dose to 800 mg of acyclovir 2 times a day with an interval of 12 hours. In patients with moderate renal impairment (creatinine clearance 10-25 ml/min) - 800 mg of acyclovir 3 times a day with an interval of 8 hours.
Children:
Treatment and prevention of infections caused by Herpes simplex viruses types 1 and 2 in immunocompromised children:
Children over 2 years of age
should take the adult dose, and
children under 2 years of age
should take half the dose.
Treatment of chickenpox:
children 6 years and older
- 800 mg 1 time / day;
Treatment should last 5 days.
For the treatment of chickenpox in children with immunodeficiency, it is necessary to consider the possibility of intravenous use of the drug.
There are no data on the prevention of recurrent herpes simplex virus infections or the treatment of herpes zoster virus infections in immunocompetent children.
In elderly patients
clearance of acyclovir decreases. Particular attention should be paid to dose reduction in elderly patients with reduced creatinine clearance. Before using large doses of acyclovir, especially in elderly patients, it is recommended to assess the degree of dehydration and creatinine clearance.
Elderly patients and patients with renal failure
have an increased risk of developing neurological side effects, these reactions are usually reversible after cessation of treatment. Long-term or repeated courses of treatment with acyclovir in immunocompromised individuals may lead to the development of virus strains with reduced sensitivity to acyclovir.
Features of application
Pregnant
There was no increase in the number of birth defects in children whose mothers used acyclovir during pregnancy compared to the general population. However, acyclovir tablets should be used only when the potential benefit of the drug for the mother outweighs the possible risk to the fetus.
When taken orally 200 mg of acyclovir 5 times a day, acyclovir passes into breast milk in concentrations of 0.6-4.1% of the corresponding level of acyclovir in the blood plasma. Potentially, a child fed with this milk can absorb acyclovir at a dose of up to 0.3 mg/kg body weight per day. Therefore, prescribing acyclovir to breastfeeding women should be done with caution, taking into account the risk/benefit ratio.
Drivers
When deciding whether to drive a car or operate machinery, the clinical status of the patient and the side effect profile of the drug should be taken into account. Studies of the effect of acyclovir on the reaction rate when driving vehicles or operating other mechanisms have not been carried out. In addition, the pharmacology of acyclovir does not give reason to expect any negative effects.
Acyclovir-Belmed tablets 400 mg No. 10x2
Name
Acyclovir-Belmed tablet 400 mg in container pack No. 10x2
Description
Dosage 400 mg: capsule-shaped, biconvex tablets, white or almost white, with a notch on one side. The notch is not intended to divide the tablet into equal parts, but can be used to break the tablet to make it easier to swallow.
Main active ingredient
Acyclovir
Release form
Pills
Dosage
400mg
pharmachologic effect
Acyclovir is a synthetic analogue of a purine nucleoside that has the ability to inhibit in vitro and in vivo human herpes viruses, including herpes simplex virus types 1 and 2, varicella zoster virus and herpes zoster virus. The inhibitory effect of acyclovir on Herpes simplex viruses type 1 and 2, Varicella zoster is highly selective. Acyclovir is not a substrate for the thymidine kinase enzyme in uninfected cells, therefore acyclovir is of low toxicity to mammalian cells. Thymidine kinase of cells infected with Herpes simplex viruses type 1 and 2, Varicella zoster converts acyclovir into acyclovir monophosphate, a nucleoside analogue, which is then sequentially converted into diphosphate and triphosphate under the action of cellular enzymes. Acyclovir triphosphate interacts with DNA polymerase and inhibits the replication of viral DNA, is included in the viral DNA chain, which leads to chain termination. In patients with severe immunodeficiency, long-term or repeated courses of acyclovir therapy may lead to the emergence of resistant strains, so further treatment may be ineffective. The majority of isolated strains with reduced sensitivity to acyclovir had a relatively low content of viral thymidine kinase and a disorder in the structure of the viral thymidine kinase or DNA polymerase. The effect of acyclovir on Herpes simplex strains in vitro can also lead to the formation of strains less sensitive to it. A correlation has not been established between the sensitivity of Herpes simplex strains to acyclovir in vitro and the clinical effectiveness of the drug.
Indications for use
- treatment of primary and recurrent infections of the skin and mucous membranes caused by the Herpes simplex virus (types 1 and 2), including genital herpes (with the exception of neonatal herpes and severe infections caused by the herpes simplex virus in children with immunodeficiency); - prevention of exacerbations of recurrent infections caused by the Herpes simplex virus (types 1 and 2) in patients with normal immune status; - prevention of primary and recurrent infections caused by the Herpes simplex virus (types 1 and 2) in patients with immunodeficiency; - chicken pox, herpes zoster (shingles).
Directions for use and doses
Acyclovir-Belmed can be taken with food, since food intake does not significantly interfere with its absorption. The tablets should be taken with a full glass of water. It is necessary to ensure that the patient is adequately hydrated when taking high doses of acyclovir. Adults - for the treatment of infections caused by Herpes simplex types 1 and 2, the recommended dose is 200 mg 5 times a day every 4 hours, except during nighttime sleep. Usually the course of treatment is 5 days, but can be extended for severe primary infections. In cases of severe immunodeficiency (eg, after bone marrow transplantation) or in cases of impaired intestinal absorption, the dose may be doubled to 400 mg, or intravenous acyclovir should be considered as an alternative. Treatment should begin as soon as possible after infection occurs; in case of relapses, it is recommended to prescribe the drug already in the prodromal period or when the first elements of the rash appear. — for suppressive treatment of infections caused by Herpes simplex types 1 and 2, in patients with normal immune status, the recommended dose is 200 mg 4 times a day every 6 hours. Many patients are suitable for a more convenient treatment regimen: 400 mg 2 times a day every 12 h. In some cases, lower doses of acyclovir are effective: 200 mg 3 times a day (every 8 hours) or 2 times a day (every 12 hours). Treatment with acyclovir should be periodically interrupted for 6-12 months to identify possible changes in the natural history of the disease. - for the prevention of infections caused by Herpes simplex types 1 and 2, in patients with immunodeficiency, the recommended dose is 200 mg 4 times a day every 6 hours. In case of severe immunodeficiency (for example, after bone marrow transplantation) or if absorption from the intestine is impaired, the dose may be doubled to 400 mg or intravenous acyclovir should be considered as an alternative. The duration of the preventive course of therapy is determined by the duration of the period of existence of the risk of infection. — for the treatment of chickenpox and herpes zoster, the recommended dose of acyclovir is 800 mg 5 times a day every 4 hours, with the exception of the period of night sleep. The course of treatment is 7 days. In cases of severe immunodeficiency (for example, after bone marrow transplantation) or in cases of impaired absorption from the intestine, intravenous acyclovir should be considered as an alternative. The drug should be prescribed as soon as possible after the onset of infection. Treatment for herpes zoster has the best results if started as soon as possible after the rash appears. Treatment of chickenpox in patients with normal immune status should begin within 24 hours after the onset of the rash. Children - treatment and prevention of infections caused by Herpes simplex viruses in children with immunodeficiency: for children aged 2 years and older, doses recommended for adults should be used. Children under two years of age should be given half the adult dose. For the treatment of neonatal herpes, intravenous acyclovir is recommended. - treatment of chickenpox: children aged 6 years and older are prescribed acyclovir 800 mg 4 times a day, 2-5 years - 400 mg 4 times a day, up to 2 years - 200 mg 4 times a day. Treatment should be continued for 5 days. More precisely, a single dose can be determined at the rate of 20 mg/kg body weight (but not more than 800 mg of acyclovir) 4 times a day. There are no data on the use of acyclovir for the prevention of relapses of infections caused by Herpes simplex viruses and in the treatment of herpes zoster in children with normal immunity. Elderly Patients The possibility of renal impairment in the elderly should be considered and the dose should be adjusted accordingly. Elderly patients taking high doses of oral acyclovir should maintain adequate hydration. Patients with renal failure It is necessary to ensure that the patient is adequately hydrated when taking high doses of acyclovir. During the treatment of infections caused by the herpes simplex virus in patients with renal failure, the use of recommended oral doses does not lead to the accumulation of acyclovir in the body at concentrations higher than those considered safe during intravenous administration of the drug. However, when treating an infection caused by the herpes simplex virus in patients with severe renal impairment (creatinine clearance less than 10 ml/min), it is recommended to adjust the dose: 200 mg of acyclovir 2 times a day after 12 hours. In the treatment of herpes zoster: it is recommended to adjust the dose to 800 mg of acyclovir 2 times a day with a 12-hour interval for patients with severe renal impairment (creatinine clearance less than 10 ml/min) and 800 mg of acyclovir 3 times a day with an interval of 8 hours - in patients with moderate renal impairment (creatinine clearance within 10-25 ml/min). Patients with hepatic impairment No dosage adjustment is required for patients with mild or moderate hepatic impairment. Clinical experience with the use of the drug in the late stages of cirrhosis (with impairment of the synthesizing function of the liver and the presence of signs of portal block) is limited, but pharmacokinetics indicators indicate that there is no need for dose adjustment. If the next dose of acyclovir is missed, the drug must be taken as soon as possible. However, if it is almost time to take the next dose of Acyclovir-Belmed, the missed dose should be omitted. Do not take a double dose of Acyclovir-Belmed to make up for a missed dose!
Use during pregnancy and lactation
The use of acyclovir during pregnancy is possible only if the expected benefit to the mother outweighs the potential risk to the fetus. There are post-marketing data on the use of various dosage forms of acyclovir in pregnant women, which do not indicate an increase in the incidence of birth defects compared to the general population. The observed birth defects were not unique, suggesting a causal relationship with acyclovir. In standard studies of systemic use of acyclovir in rabbits, mice and rats, embryotoxic and teratogenic effects were not detected. In unconventional studies on female rats, the occurrence of congenital malformations was observed only after subcutaneous administration of high doses, which also caused toxic symptoms in mothers. The clinical significance of these observations is unknown. After oral administration of acyclovir at a dose of 200 mg five times a day, its concentration in breast milk ranged from 60% to 410% of the drug concentration determined in blood plasma. This concentration of acyclovir in breast milk could lead to the drug being supplied to the child at a daily dose of up to 0.3 mg/kg body weight/day. Therefore, special care should be taken when using the drug in nursing mothers. Fertility. There is no data on the effect of acyclovir on fertility in women. In a study of 20 men with normal sperm counts who took oral acyclovir at a dose of up to 1.0 g per day for up to 6 months, there was no significant clinical effect on sperm morphology, count or motility.
Precautionary measures
When treating genital herpes, sexual contact should be avoided, since acyclovir does not prevent sexual transmission of herpes. During the period of use of the drug, it is necessary to monitor kidney function. State of hydration. In patients receiving high doses of acyclovir, care should be taken to ensure adequate hydration. To prevent the formation of acyclovir crystals in the renal tubules, it is recommended to take large amounts of fluid during the treatment period. The risk of renal failure increases when taken together with other nephrotoxic drugs. Elderly patients and patients with renal impairment have an increased risk of developing neurological side effects, these reactions are usually reversible after discontinuation of treatment. Long-term or repeated courses of treatment with acyclovir in immunocompromised individuals may lead to the development of virus strains with reduced sensitivity to acyclovir. Available clinical trial data are not sufficient to suggest that treatment with acyclovir reduces the incidence of herpes zoster complications in immunocompromised patients. No dose adjustment is required for patients with mild or moderate liver dysfunction. Clinical experience with the use of the drug in the late stages of cirrhosis (with impairment of the synthesizing function of the liver and the presence of signs of portal block) is limited, but pharmacokinetics indicators indicate that there is no need for dose adjustment. Acyclovir-Belmed tablets contain lactose, so patients with rare hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this drug.
Interaction with other drugs
Acyclovir is excreted mainly in the urine by active renal tubular secretion unchanged. Any medications used simultaneously; which are eliminated in the same way, can compete with acyclovir and increase its concentration in the blood plasma. Probenecid and cimetidine increase the AUC of acyclovir through this mechanism and also decrease the renal clearance of acyclovir. Plasma AUCs of acyclovir and the inactive metabolite of mycophenolate mofetil, an immunosuppressive drug used in transplantation, similarly increase when administered concomitantly. However, no dose adjustment is required due to the broad therapeutic index of acyclovir. A pilot study in five men showed an approximately 50% increase in theophylline concentrations when taken concomitantly with acyclovir. It is recommended to measure plasma theophylline concentrations during concomitant therapy with acyclovir.
Contraindications
Increased individual sensitivity to acyclovir or valacyclovir, or to any of the excipients.
Compound
Each tablet contains the active substance: acyclovir - 400 mg; excipients: microcrystalline cellulose, sodium starch glycolate (type A), povidone, magnesium stearate, lactose monohydrate.
Overdose
Acyclovir is only partially absorbed from the gastrointestinal tract. When taking acyclovir up to 20 g at a time, as a rule, no toxic effects are observed. In case of unintentional repeated (over several days) oral overdose, gastrointestinal effects (such as nausea and vomiting) and neurological effects (headache and confusion) are observed. Treatment: symptomatic. Hemodialysis significantly accelerates the removal of acyclovir from the blood and therefore may be considered as a treatment option in cases of symptomatic overdose.
Side effect
The frequency of side effects is given in the following gradation: very often (? 1/10); often (?1/100,
Storage conditions
In a place protected from moisture and light at a temperature not exceeding 25 °C. Keep out of the reach of children.
Overdose
Symptoms
Acyclovir is only partially absorbed from the gastrointestinal tract. Patients have been reported to accidentally ingest up to 20 g of acyclovir internally without causing toxic effects. In case of accidental repeated oral overdose of oral acyclovir, gastroenterological (such as nausea and vomiting) and neurological symptoms (headache and confusion) occur over several days. In case of an overdose of intravenous acyclovir, the level of serum creatinine and blood urea nitrogen increases, which leads to renal failure. Neurological manifestations of overdose may include confusion, hallucinations, agitation, seizures and coma.
Treatment
The patient must be carefully examined to identify symptoms of intoxication. Since acyclovir is well removed from the blood by hemodialysis, the latter should be used in case of overdose.
Aciclovir forte
Inside. The drug is taken during or immediately after a meal and washed down with a sufficient amount of water.
The dosage regimen is set individually depending on the severity of the disease.
When treating infections of the skin and mucous membranes caused by Herpes simplex types I and II:
Adults: the drug is prescribed 200 mg 5 times a day for 5 days at 4-hour intervals during the day and at 8-hour intervals at night. In more severe cases of the disease, the course of treatment can be extended as prescribed by a doctor to 10 days. As part of complex therapy for severe immunodeficiency, including with a full-blown clinical picture of HIV infection (including early clinical manifestations of HIV infection and the stage of AIDS), after bone marrow implantation, 400 mg is prescribed 5 times a day.
To prevent relapses of infections caused by Herpes simplex viruses type I and II, patients with normal immune status and in case of relapse of the disease are prescribed 200 mg 4 times a day every 6 hours, course duration is from 6 to 12 months.
For the prevention of infections caused by Herpes simplex viruses type I and II in adults with immunodeficiency, the drug is recommended to be prescribed 200 mg 4 times a day every 6 hours, the maximum dose is up to 400 mg of acyclovir 5 times a day, depending on the severity of the infection.
Children: For Herpes simplex infection and prevention of this infection in patients with weakened immune defenses, children over 3 years of age receive the same dose as adults.
When treating infections caused by Varicella zoster:
Adults: the drug is prescribed 800 mg 5 times a day every 4 hours during the day and at 8-hour intervals at night. The duration of treatment is 7-10 days.
Children: for chickenpox, prescribe 20 mg/kg 4 times a day for 5 days (maximum single dose 800 mg), children from 3 years to 6 years: 400 mg 4 times a day, over 6 years: 800 mg 4 times per day for 5 days.
When treating infections caused by Herpes zoster, adults are prescribed 800 mg 4 times a day every 6 hours for 5 days.
In patients with impaired renal function:
When treating and preventing infections caused by Herpes simplex in patients with creatinine clearance less than 10 ml/min, the dosage of the drug should be reduced to 200 mg 2 times a day at 12-hour intervals.
When treating infections caused by Varicella zoster in patients with creatinine clearance less than 10 ml/min, it is recommended to reduce the dosage of the drug to 800 mg 2 times a day at 12-hour intervals; with creatinine clearance up to 25 ml/min, 800 mg is prescribed 3 times a day at 8-hour intervals.
Side effects
From the blood and lymphatic system: anemia, thrombocytopenia, leukopenia.
From the immune system: anaphylaxis.
Mental disorders and disorders of the nervous system: headache, dizziness, agitation, confusion, tremor, ataxia, dysarthria, hallucinations, psychotic symptoms, convulsions, drowsiness, encephalopathy, coma.
The above neurological reactions are generally reversible and usually occur in patients with renal failure or other risk factors.
From the respiratory system and chest organs: shortness of breath.
From the digestive system: nausea, vomiting, diarrhea, abdominal pain.
From the hepatobiliary system: reversible increase in the level of bilirubin and liver enzymes, jaundice, hepatitis.
From the skin and subcutaneous tissue: itching, rash (including photosensitivity), urticaria, increased diffuse hair loss (since hair loss can be associated with a large number of diseases and medications, a clear connection with acyclovir was not found), angioedema.
From the kidneys and urinary system: increased levels of urea and creatinine in the blood, acute renal failure, pain in the kidneys.
Kidney pain may be associated with renal failure and crystalluria.
Acyclovir forte-Alium tablets 400 mg No. 20
Acyclovir forte-Alium tablets 400mg No. 20
Acyclovir Buy Acyclovir in
DOSAGE FORMS tablets 0.4g tablets 400mg
MANUFACTURERS Obolenskoye FP (Russia)
GROUP Antiherpetic drugs
COMPOSITION Active substance: Acyclovir.
INTERNATIONAL NON-PROPENTED NAME Acyclovir
SYNONYMS Acigerpin, Acic-ophthal, Acyclovir Belupo, Acyclovir Hexal, Acyclovir Sandoz, Acyclovir forte, Acyclovir-Akos, Acyclovir-Acri, Acyclostad, Vero-Acyclovir, Vivorax, Virolex, Gervirax, Herpevir, Herperax, Herpesin, Zovirax, Lovir, Medovir , Tsevirin, Cycloviral Sediko
PHARMACOLOGICAL ACTION Antiviral. It has a highly selective effect on herpes simplex viruses type 1 and 2, herpes zoster, Epstein-Barr and cytomegalovirus. Easily passes through the corneal epithelium (eye ointment) and creates a therapeutic concentration in the ocular fluid. When used topically in the form of a cream, it is not absorbed into the systemic circulation. Penetrates through the BBB and placental barrier, excreted in breast milk. In case of herpes, it prevents the formation of new rash elements, reduces the likelihood of skin dissemination and visceral complications, accelerates the formation of crusts, and reduces pain in the acute phase of herpes zoster. Has an immunostimulating effect.
INDICATIONS FOR USE Primary and recurrent herpetic lesions of the skin and mucous membranes (including genital herpes), herpetic lesions in patients with immunodeficiency (treatment and prevention), herpes zoster, chicken pox, simple herpetic keratitis.
CONTRAINDICATIONS Hypersensitivity, breastfeeding.
SIDE EFFECTS Headache, fatigue, neurological disorders, shortness of breath, nausea, vomiting, diarrhea, intestinal colic, increased body temperature, edema, lymphadenopathy, increased levels of bilirubin, urea, creatinine, transient increase in the activity of liver transaminases, allergic reactions in the form of skin rash, itching. With intravenous administration - agitation, impaired consciousness, lethargy, tremor, convulsions, hallucinations, psychosis, coma; reactions at the IV injection site - local inflammation, phlebitis. When used externally - erythema, peeling, burning sensation, burn.
INTERACTION Probenecid slows down excretion (blocks tubular secretion).
METHOD OF APPLICATION AND DOSAGE Orally, adults and children over 2 years old - 0.2 g 5 times a day (except at night), for prevention - 0.2 g 4 times a day; for herpes zoster - 0.8 g 4 times a day; children under 2 years old - half the dose for adults. The course of treatment is usually 5 days, for herpes zoster - another 3 days after the signs of the disease disappear. Preventive treatment for organ transplantation is carried out for 6 weeks.
OVERDOSE Symptoms: headache, neurological disorders, shortness of breath, nausea, vomiting, diarrhea, renal failure, lethargy, convulsions, coma. Treatment: maintenance of vital functions, hemodialysis.
SPECIAL INSTRUCTIONS Restrictions on use: Pregnancy. To prevent crystallization in the tubular apparatus, it is recommended to take large amounts of liquid. Caution should be exercised in patients with psychoneurotic disorders, impaired renal and liver function, electrolyte disturbances, and severe hypoxia. It is recommended to apply the cream using rubber gloves to prevent infection of other areas of the skin. For more detailed information, see the instructions for use.
STORAGE CONDITIONS: In a dry place, at a temperature not exceeding 25 °C.
Note!
Description of the drug Acyclovir 400 Herds table. 400 mg No. 35 on this page is a simplified author’s version of the apteka911 website, created on the basis of the instructions for use.
Before purchasing or using the drug, you should consult your doctor and read the manufacturer's original instructions (attached to each package of the drug). Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.
